Log In Sign up
The largest database of trusted experimental protocols

Mcdb 105

Manufactured by Merck Group
Visit Supplier
Sourced in United States, Germany, Canada

MCDB 105 is a laboratory equipment product manufactured by Merck Group. It is designed to perform specific functions in a laboratory setting. The core function of MCDB 105 is to provide a controlled environment for various laboratory processes and experiments.

Automatically generated - may contain errors

Lab products found in correlation

Skov3, by American Type Culture Collection (14 mentions) Insulin, by Merck Group (11 mentions) Medium 199, by Merck Group (11 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (8 mentions) Medium 199, by Thermo Fisher Scientific (8 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (8 mentions) Fetal bovine serum (fbs), by Merck Group (7 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (7 mentions) Ovcar3, by American Type Culture Collection (6 mentions) Hydrocortisone, by Merck Group (5 mentions) A2780, by American Type Culture Collection (5 mentions) Bovine pituitary extract, by Thermo Fisher Scientific (5 mentions) Rpmi 1640 medium, by Thermo Fisher Scientific (5 mentions) M199 medium, by Merck Group (4 mentions) Penicillin, by Merck Group (4 mentions) Streptomycin, by Merck Group (4 mentions) L glutamine, by Merck Group (3 mentions) Media 199, by Merck Group (3 mentions) Human albumin, by Merck Group (3 mentions) A2780, by Corning (3 mentions)

Close spelling variants of this product

MCDB 105 media (4 citations) MCDB 105/Medium 199 (4 citations) Ham’s F12: MCDB 105 (2 citations)

68 protocols using mcdb 105

1

Cell Line Maintenance and Characterization

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
A2780 cells and ES-2 cells were maintained in MCDB105 and M199 (1:1) (Sigma, USA) containing 5% FBS (Sigma), OV90 cells were maintained in MCDB105 and M199 (1:1) with 15% FBS. OVCA420* cells were cultured in DMEM (Sigma and Caisson Labs, USA) supplemented with 10% FBS. All the media were supplemented with 100 units/MI penicillin and 100 µg/mL streptomycin. All cell lines were subjected to cell line identity confirmation. A2780-Cas9 stable cells were established by lentiviral transducing A2780 cells with pLenti-cas9 followed by selection with 400 µg/mL blasticidin for 2 weeks. ES-2, OVCA420* and OV90 cells were gifts from Dr. Viji Shridhar (Mayo Clinic). A2780 cell was from Dr. Andrew Godwin (The University of Kansas Medical Center). All experiments performed on cells that were passaged <20 times. Mycoplasma testing was performed during the studies, and cell cultures were free of mycoplasma. Cell line identification was performed at the end of experiments. OV90 showed 100% STR profiles matching to corresponding cell lines reported in ATCC or ExPASy. STR profiles for ES-2 and A2780 were performed in 2014 as a supplement to our recent publication60 (link). STR profiles for OVCA420* does not match with any reported cell lines in ATCC, ExPASy, DSMZ, or CLIMA, and therefore we placed an asterisk to differentiate it from the original cell line.
Fang P., De Souza C., Minn K, & Chien J. (2019). Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity. Communications Biology, 2, 335.
+ Open protocol
+ Expand
2

Establishment of Cisplatin-Resistant Ovarian Cancer Cell Lines

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
The human ovarian cancer PEO1 and PEO4 cells (Sigma) were cultured in RPMI-1640 with 10% Fetal Bovine Serum (FBS). IGROV1 cells (a generous gift form Wei Zheng) was cultured in DMEM with 10% FBS. OV90 (ATCC) was cultured in the growth medium containing 1:1 MCDB 105 (Sigma) and M199 (Sigma) supplemented with 10% FBS. All the cells were cultured at 37 °C in a humidified incubator containing 5% CO2.
Cisplatin resistant cell lines IGROV1 CR and OV90 CR were established by following the previous report40 (link). Briefly, IGROV1 and OV90 cells were treated with cisplatin for six cycles (4 hours of cisplatin treatment, followed by release to cisplatin free medium for three weeks). In the next cycle, cisplatin treatment was repeated with an increased concentration of cisplatin. After five months of treatment (6 cycles), cisplatin resistant cell lines IGROV1 CR and OV90 CR were obtained. Only early-passage (<10 passages) resistant cell lines were used for the study.
Sun J., Cai X., Yung M.M., Zhou W., Li J., Zhang Y., Li Z., Liu S.S., Cheung A.N., Ngan H.Y., Li Y., Dai Z., Kai Y., Tzatsos A., Peng W., Chan D.W, & Zhu W. (2018). miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene, 38(4), 564-580.
+ Open protocol
+ Expand
3

Cultivation of Mucinous Ovarian Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The EFO-27 cell line is commercially available and was originally derived from a solid metastasis of a mucinous papillary ovarian carcinoma68 (link). The GTFR230 mucinous ovarian cancer cell line was created in house and derived from a stage IC low grade primary mucinous ovarian cancer collected as part of the Gynecological Tissue and Fluid Repository (GTFR) at the University of Southern California (USC). We routinely profile cell lines using STR profiling (using the Powerplex 16 panel) at the University of Arizona Genetics Core facility and screen for mycoplasma using a mycoplasma-specific PCR. A piece of the tissue removed during surgery was transferred to the cell culture laboratory, minced into small pieces (1–2 mm diameter) and placed into NOSE-CM69 (link) which consists of Medium 199 mixed in a 1:1 ratio with MCDB105 (Sigma), 15% fetal bovine serum (FBS, Hyclone), 10 ng/ml epidermal growth factor (EGF), 34 μg/ml bovine pituitary extract (Life Technologies), 500ng/ml hydrocortisone and 5 μg/ml insulin (Sigma). Cells were confirmed to be epithelial in origin by staining for cytokeratin.
Kelemen L.E., Lawrenson K., Tyrer J., Li Q., M. Lee J., Seo J.H., Phelan C.M., Beesley J., Chen X., Spindler T.J., Aben K.K., Anton-Culver H., Antonenkova N., Baker H., Bandera E.V., Bean Y., Beckmann M.W., Bisogna M., Bjorge L., Bogdanova N., Brinton L.A., Brooks-Wilson A., Bruinsma F., Butzow R., Campbell I.G., Carty K., Chang-Claude J., Chen Y.A., Chen Z., Cook L.S., Cramer D.W., Cunningham J.M., Cybulski C., Dansonka-Mieszkowska A., Dennis J., Dicks E., Doherty J.A., Dörk T., du Bois A., Dürst M., Eccles D., Easton D.T., Edwards R.P., Eilber U., Ekici A.B., Engelholm S.A., Fasching P.A., Fridley B.L., Gao Y.T., Gentry-Maharaj A., Giles G.G., Glasspool R., Goode E.L., Goodman M.T., Grownwald J., Harrington P., Harter P., Hasmad H.N., Hein A., Heitz F., Hildebrandt M.A., Hillemanns P., Hogdall E., Hogdall C., Hosono S., Iversen E.S., Jakubowska A., Jensen A., Ji B.T., Karlan B.Y., Kellar M., Kelley J.L., Kiemeney L.A., Krakstad C., Kjaer S.K., Kupryjanczyk J., Lambrechts D., Lambrechts S., Le N.D., Lee A.W., Lele S., Leminen A., Lester J., Levine D.A., Liang D., Lissowska J., Lu K., Lubinski J., Lundvall L., Massuger L.F., Matsuo K., McGuire V., McLaughlin J.R., McNeish I., Menon U., Modugno F., Moes-Sosnowska J., Moysich K.B., Narod S.A., Nedergaard L., Ness R.B., Nevanlinna H., Azmi M.A., Odunsi K., Olson S.H., Orlow I., Orsulic S., Weber R.P., Paul J., Pearce C.L., Pejovic T., Pelttari L.M., Permuth-Wey J., Pike M.C., Poole E.M., Ramus S.J., Risch H.A., Rosen B., Rossing M.A., Rothstein J.H., Rudolph A., Runnebaum I.B., Rzepecka I.K., Salvesen H.B., Schildkraut J.M., Schwaab I., Shu X.O., Shvetsov Y.B., Siddiqui N., Sieh W., Song H., Southey M.C., Sucheston L., Tangen I.L., Teo S.H., Terry K.L., Thompson P.J., Tworoger S.S., van Altena A.M., Van Nieuwenhuysen E., Vergote I., Vierkant R.A., Wang-Gohrke S., Walsh C., Wentzensen N., Whittemore A.S., Wicklund K.G., Wilkens L.R., Wlodzimierz S., Woo Y.L., Wu X., Wu A.H., Yang H., Zheng W., Ziogas A., Sellers T.A., Freedman M.L., Chenevix-Trench G., Pharoah P.D., Gayther S.A, & Berchuck A. (2015). Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature genetics, 47(8), 888-897.
+ Open protocol
+ Expand
4

Ovarian Cancer Cell Line Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human EOC cell lines (OVCAR3, Caov3, OVCA429, SKOV3 and A2780) and normal Human Ovarian Surface Epithelial (HOSE) cells were acquired from the China Center for Type Culture Collection (CCTCC). The COV644 cell line was purchased from Sigma (St. Louis, MO). EOC cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum and antibiotics (Gibco). HOSE cells were cultured in medium containing 1:1 mixture of MCDB 105 and M199 medium (Sigma). All cells were incubated at 37°C in a humidified atmosphere containing 5% CO2.
Xia B., Yang S., Liu T, & Lou G. (2015). miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Molecular Cancer, 14, 57.
+ Open protocol
+ Expand
5

Culturing Thyroid Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human thyroid epithelial cell line Nthy-ori3-1, PTC cell lines K1 and TPC-1 were cultured. Nthy-ori3-1 and K1 were purchased from the European Collection of Cell Cultures and TPC-1 was gifted by Professor Lei Yang (China Medical University, China). K1 was cultured in a medium mixture of Dulbecco's modified Eagle's medium, Ham's F12 (Corning Life Sciences, NY, USA) and MCDB105 (Sigma-Aldrich St.Louis, Missouri) at a 1:2:1 ratio, which supplemented with 10% fetal bovine serum (FBS; Gibco Co., Grand Island, NY, USA), 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L glutamine (Sigma-Aldrich). Nthy-ori3-1 and TPC-1 were grown in Roswell Park Memorial Institute-1640 medium (Corning Life Sciences, NY, USA) and supplemented with 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L glutamine in a humidified incubator with 5% CO2 at 37°C.
Wang L., Huang Y., Liu C., Guo M., Ma Z., He J., Wang A., Sun X, & Liu Z. (2021). Deltex3 inhibits Epithelial Mesenchymal Transition in Papillary Thyroid Carcinoma via promoting ubiquitination of XRCC5 to regulate the AKT signal pathway. Journal of Cancer, 12(3), 860-873.
+ Open protocol
+ Expand
6

Culturing Human Cervical Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
We obtained SiHa, HeLa, CaSki, ME-180 and C33A human cervical cancer cell lines from the American Type Culture Collection (Rockville, MD). Squamous cervical carcinoma and HeLa cells were cultured in Dulbecco's Modified Eagle Medium; ME-180 and C33A cells were cultured in Eagle's Minimum Essential Medium (Gibco-BRL, Gaithersburg, MD, USA) ; CaSki cells were cultured in RPMI-1640 medium (Gibco-BRL). The human normal ovarian cancer cell line HOSE was cultured in MCDB 105 (Sigma Aldrich, Castle Hill, Australia) medium. Culture media were supplemented with 10% (v/v) fetal bovine serum and penicillin/streptomycin. All cell lines were maintained at 37°C in a humidified incubator with 5% CO2.
Kim H.J., Eoh K.J., Kim L.K., Nam E.J., Yoon S.O., Kim K.H., Lee J.K., Kim S.W, & Kim Y.T. (2016). The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer. Oncotarget, 7(50), 83001-83016.
+ Open protocol
+ Expand
7

Culturing Ovarian Cancer Cell Lines

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
IGROV1 cells (a generous gift form Wei Zheng), U2OS (HTB-96; ATCC), HEK293T (CRL-11268; ATCC) and SKOV3 cells (HTB-77; ATCC) were cultured at 37 °C in DMEM with 10% Fetal Bovine Serum (FBS). PEO1 (10032308; Sigma-Aldrich), PEO4 (10032309; Sigma-Aldrich), PEO14 (10032311; Sigma-Aldrich) and PEO23 cells (10032313; Sigma-Aldrich) were cultured at 37 °C in RPMI-1640 with 10% FBS. OV90 (CRL-11732; ATCC) was cultured in medium containing 1:1 MCDB 105 (Sigma) and M199 (Sigma) supplemented with 10% FBS at 37 °C. All the cells were cultured at in a humidified incubator with 5% CO2 atmosphere.
Cisplatin resistant cell lines, including SKOV3 CR, IGROV1 CR, and OV90 CR, were generated using approach as we previously reported4 (link).
Li J., Wu R., Yung M.M., Sun J., Li Z., Yang H., Zhang Y., Liu S.S., Cheung A.N., Ngan H.Y., Braisted J.C., Zheng W., Wei H., Gao Y., Nemes P., Pei H., Chan D.W., Li Y, & Zhu W. (2021). SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. Cell Death & Disease, 12(4), 341.
+ Open protocol
+ Expand
8

Ovarian Cancer Cell Line Cultivation

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Ovarian cancer cell lines were obtained from the European Collection of Authenticated Cell Cultures (ECACC), and cultured based on the guidelines of the repository. Cells were regularly tested for mycoplasma infection and discontinued after 15 consecutive passages. Some of these lines were established from the same patient during the course of disease, and had received different treatment schemes prior to their establishment: PEA1/PEA2, PEO1/PEO4/PEO6 and PEO14/PEO23/T014 [43 (link)]. The cells were maintained in Roswell Park Memorial Institute (RPMI) or Dulbecco’s Modified Eagle Medium (DMEM) (Lonza, Basel, Switzerland) supplemented with 10% Fetal Bovine Serum (FBS) and 100 U/ml penicillin–streptomycin (Sigma-Aldrich, MO, USA). Immortalized Ovarian Surface Epithelium (IOSE) cells were obtained from the Canadian OvCaRe Cell Bank and grown in a combination of 199 and MCDB105 (1:1) media (Sigma-Aldrich) with 5% FBS and 50 µg/ml gentamicin. All cells were incubated at 37° C in a 5% CO2 incubator. Spheroids were cultured using ULA plates (Corning, NY, USA) as previously described [10 (link)], for up to 14 days.
Heredia-Soto V., Redondo A., Berjón A., Miguel-Martín M., Díaz E., Crespo R., Hernández A., Yébenes L., Gallego A., Feliu J., Hardisson D, & Mendiola M. (2018). High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease. Oncotarget, 9(31), 21893-21903.
+ Open protocol
+ Expand
9

Comprehensive Cell Imaging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
TRITON X-100, Trizma Base, Trichloroacetic acid solution (TCA), Sulforhodamine-B Sodium salt, CID-1067700, Geranylgeranyl pyrophosphate ammonium salt (GGPP), Simvastatin, DMSO, MCDB105 and Medium199 were purchased from Sigma Aldrich (Stockholm, Sweden). Carboplatin was purchased from Selleck Chemicals (SMS-gruppen, Rungsted, Denmark). Phalloidin CruzFluor™ 488 Conjugate was purchased from Santa Cruz (AH diagnostics AB, Solna, Sweden). Penicillin/Streptomycin solution (P/S), Fetal Bovine Serum (FBS), DPBS, DMEM: F12, RPMI1640 and Dulbecco’s Modified Eagle’s Medium (DMEM) were purchased from Nordic Biolabs (Täby, Sweden). Paraformaldehyde 16% w/v (PFA) was purchased from VWR (Spånga, Sweden). DAPI was purchased from Thermo Fisher (Göteborg, Sweden). Pan Caspase inhibitor Z-VAD-FMK was purchased from Promega (Nacka, Sweden).
Arildsen N.S, & Hedenfalk I. (2020). Simvastatin is a potential candidate drug in ovarian clear cell carcinomas. Oncotarget, 11(40), 3660-3674.
+ Open protocol
+ Expand
10

Derivation and Culture of Human Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The 911 human embryonic retinoblasts derived by transformation with a plasmid containing 79–5789 bp of the Ad5 genome [49 (link)] were obtained through Crucell Holland B.V. (Leiden, The Netherlands). The human lung carcinoma cell line A549, ovarian adenocarcinoma cell line OVCAR3 and OV-4 were obtained from American Cell Type Culture Collection (ATCC, Manassas, Virginia USA). The human ovarian carcinoma cell line SKOV3.ip1 was obtained from Janet Price (M. D. Anderson Cancer Center, Houston, Tex.). The normal ovarian surface epithelial cells IOSE-120 (Passage 8) and IOSE-523 (Passage 8), which were obtained from healthy women and immortalized with SV40 T/t were received from Canadian OvCaRe Cell Bank (Vancouver, B.C., Canada). The IOSE-120 and IOSE-523 cells were maintain in a combination of 199 (Sigma M5017) and MCDB105 (Sigma M6395) medium (1:1) supplemented with 5 % FBS and 50 μg/ml gentamicin. All cell lines were grown at 37 °C in medium recommended by the suppliers in a humidified atmosphere of 5 % CO2.
Ashshi A.M., El-Shemi A.G., Dmitriev I.P., Kashentseva E.A, & Curiel D.T. (2016). Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer. Journal of Ovarian Research, 9, 38.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!